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Key Points Summary: 1 
• Intermittent hypoxia leads to long-lasting increases in muscle sympathetic nerve activity 2 
and blood pressure contributing to increased risk for hypertension in obstructive sleep 3 
apnoea patients. 4 
• We determined whether augmented vascular responses to increasing sympathetic 5 
vasomotor outflow, termed sympathetic neurovascular transduction (sNVT), 6 
accompanied changes in blood pressure following acute intermittent hypercapnic hypoxia 7 
(IH) in men. 8 
• Lower body negative pressure was utilized to induce a range of sympathetic 9 
vasoconstrictor firing while measuring beat-by-beat blood pressure and forearm vascular 10 
conductance. 11 
• IH reduced vascular shear stress and steepened the relationship between diastolic blood 12 
pressure and sympathetic discharge frequency suggesting greater systemic sNVT. 13 
• Our results indicate that recurring cycles of acute IH characteristic of obstructive sleep 14 
apnoea could promote hypertension by increasing sNVT.  15 
 3 
ABSTRACT 16 
Acute intermittent hypercapnic hypoxia (IH) induces long-lasting elevations in sympathetic 17 
vasomotor outflow and blood pressure in healthy humans.  It is unknown whether IH alters 18 
sympathetic neurovascular transduction (sNVT), measured as the relationship between 19 
sympathetic vasomotor outflow and either forearm vascular conductance (FVC; regional sNVT) 20 
or diastolic blood pressure (DBP; systemic sNVT).  We tested the hypothesis that IH augments 21 
sNVT by exposing healthy males to 40 consecutive 1-minute breathing cycles, each comprising 22 
40-seconds of hypercapnic hypoxia (PETCO2: +4±3 mm Hg above baseline; PETO2: 48±3 mm 23 
Hg) and 20-seconds of normoxia (n=9), or a 40-minute air-breathing control (n=7).  Before and 24 
after the intervention, lower body negative pressure (LBNP; 3 minutes at -15, -30, and -45 25 
mmHg) was applied to elicit reflex increases in muscle sympathetic nerve activity (MSNA, 26 
fibular microneurography) while clamping end-tidal gases at baseline levels.  Ventilation, arterial 27 
pressure (SBP, DBP, MAP), brachial artery blood flow (Q̇BA), FVC (Q̇BA/MAP), and MSNA 28 
burst frequency were measured continuously.  Following IH, but not control, ventilation (5 l/min; 29 
95% CI: 1 - 9), and MAP (5 mmHg; 95% CI: 1 - 9) were increased, while FVC (-0.2 ml/min/mm 30 
Hg; 95% CI: -0.0 - -0.4) and mean shear rate (SR; -21.9 /s; 95% CI: -5.8 - -38.0; all P<0.05) 31 
were reduced.  Systemic sNVT was increased following IH (0.25 mm Hg/burst/min; 95% CI: 32 
0.01 – 0.49; P<0.05), while changes in regional forearm sNVT were similar between IH and 33 
sham.  Reductions in vessel wall shear stress and consequently nitric oxide production, may 34 
contribute to heightened systemic sNVT and provide a potential neuro-vascular mechanism for 35 
elevated blood pressure in obstructive sleep apnoea. 36 
 37 
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Obstructive sleep apnoea (OSA) is characterized by repeated obstructions of the upper airway 42 
during sleep (Dempsey et al., 2010), leading to periods of intermittent hypercapnic hypoxia (IH).  43 
Longitudinal and cross-sectional epidemiological studies have established a link between the 44 
presence of OSA and both the development and the presence of hypertension (Peppard et al., 45 
2000; Kasai et al., 2012; Floras, 2018).  The observed acute and chronic effects of OSA on both 46 
night- and day-time efferent sympathetic vasoconstrictor nerve firing (Somers et al., 1995; 47 
Taylor et al., 2017) are consistent with the concept that such hypertension is of neurogenic 48 
origin.  However, many patients with OSA do not manifest hypertension, which suggests 49 
variation between individuals in their susceptibility to pro-hypertensive neural, inflammatory, 50 
and vascular stimuli induced by repeated exposure to IH (Floras, 2018). 51 
Following periods of IH, activation of the angiotensin-II type-I receptor (AT1R) (Fletcher 52 
et al., 1999; Marcus et al., 2010; Foster et al., 2010; Jouett et al., 2016) has been shown to 53 
contribute to the increased sympathetic vasomotor outflow and blood pressure observed in both 54 
healthy humans (Foster et al., 2009, 2010; Gilmartin et al., 2010; Tremblay et al., 2016; Jouett et 55 
al., 2017) and animal models (Brooks et al., 1997; Fletcher, 2000; Marcus et al., 2009).  This 56 
response depends on peripheral chemoreceptor afferent activity (Fletcher et al., 1992) and 57 
afferent-efferent translation within brainstem centers, the median pre-optic nucleus and the 58 
subfornical organs (Saxena et al., 2015; Shell et al., 2019).  IH can also reduce nitric oxide (NO) 59 
bioavailability (Foster et al., 2009; Pialoux et al., 2011), contributing to reductions in endothelial 60 
function (Gilmartin et al., 2010; Khayat et al., 2017), as well as reduce vascular sensitivity to 61 
exogenous norepinephrine (in animals) (Phillips, 2003).  The translation of increases in post-62 
ganglionic muscle sympathetic nerve activity (MSNA) to changes in vascular tone (i.e., 63 
sympathetic neurovascular transduction [sNVT]) is the final effector of the peripheral 64 
chemoreceptor reflex arc and may be augmented by IH-induced increases in renin-angiotensin 65 
system activity (Story & Ziogas, 1987), and reduced NO bioavailability (Macarthur et al., 2011).  66 
While enhanced sNVT has been observed during acute continuous hypoxia (Tan et al., 2013b), 67 
whether sNVT changes following periods of IH is unclear.  An IH-mediated increase in sNVT 68 
could, in part, contribute to the onset of arterial hypertension in some patients with OSA. 69 
 5 
The primary objective of this study was to determine if acute IH could augment regional 70 
and systemic sNVT in healthy men.  The IH paradigm utilized in this study was designed to 71 
simulate the blood gas changes observed in patients with severe OSA.  We hypothesized that 72 
sNVT would be augmented by 40-minutes of IH compared with an air-breathing time control.  73 
Blood pressure, forearm blood flow (Q̇BA) and MSNA were recorded continuously during 74 
baseline and three stages of lower body negative pressure (LBNP) to estimate sNVT.  LBNP was 75 
applied to induce reflexively greater efferent sympathetic discharge via graded baroreceptor 76 
unloading (Floras et al., 2001). 77 
78 
 6 
MATERIALS AND METHODS 79 
Ethical Approval 80 
Ethical approval was obtained from the Clinical Research Ethics Board at the University of 81 
British Columbia (H16-02525) and conformed to the Declaration of Helsinki with the exception 82 
of registration as a clinical trial.  Written informed consent was obtained from all participants.   83 
 84 
Study Participants 85 
Non-obese (BMI < 30 kg/m2), normotensive (SBP <135 mm Hg, DBP < 85 mm Hg), men were 86 
invited to participate in this study.  Participants were excluded if they were taking any 87 
medications (prescribed or over-the-counter), smoked tobacco within the past year, or had a 88 
history of hypertension, impaired renal function, liver disease, heart failure, myocardial 89 
infarction, coronary artery disease, stroke, chronic obstructive pulmonary disease, asthma, 90 
diabetes, or sleep disordered breathing.  All participants underwent pulmonary function testing 91 
(V62J, Sensormedics, Yorba Linda, CA), and values were compared against age and height 92 
dependent predictions for normative spirometry (Knudson et al., 1983) and diffusing capacity 93 
(Crapo & Morris, 1981) measurements.  Participants were excluded if their forced expiratory 94 
volume in 1 second (FEV1) / forced vital capacity ratio was < 0.70.  Participants underwent a 95 
single night of sleep with nocturnal pulse oximetry (WristOx2, Model 3150, Nonin, Plymouth, 96 
MN, USA) and were excluded if they had indications of undiagnosed sleep apnoea, defined as an 97 
oxygen desaturation index ≥ 5 events/hr (based on a desaturation ≥ 4%; nVision V6.4, Nonin).  98 
Finally, only male participants were enrolled as women are less likely to develop OSA (Peppard 99 
et al., 2013), less sensitive to alpha-adrenergic stimulation (both alpha 1 and 2) (Schmitt et al., 100 
2010) and have greater beta-adrenergic sensitivity due to oestrogen-dependent increases in beta-101 
adrenoceptor expression (Riedel et al., 2019). 102 
 103 
Experimental Protocol 104 
In preparation for the experimental protocol, participants fasted for ≥ 4 hours and abstained from 105 
exercise, caffeine, and alcohol for ≥ 12 hours.  Upon arrival at the laboratory, participants voided 106 
their bladder and lay supine with legs and hips inside a custom-built lower body negative 107 
pressure (LBNP) chamber, which was sealed at the iliac crest.  Participants were instrumented 108 
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for measures of heart rate (HR, lead-II electrocardiogram, FE 132, AD Instruments, Colorado 109 
Springs, CO), systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial 110 
pressure (MAP) (finger pulse photoplethysmography, Finometer Pro, Finapres Medical Systems, 111 
Amsterdam, Netherlands), brachial artery mean blood velocity (BA MBV) and diameter (Duplex 112 
ultrasound, ML6-15 probe, Vivid E9, GE Medical Systems, Mississauga, Canada), fibular 113 
MSNA (Nerve Traffic Analysis System Model 662C-4, University of Iowa Bioengineering, Iowa 114 
City, IA), finger SPO2 (7500FO, Nonin Medical Inc., Plymouth, MN) and a facemask to measure 115 
ventilation (V̇I) and control end-tidal gases.  V̇I was measured using a pneumotachograph (HR 116 
800L, Hans Rudolph, Shawnee, KS) and differential pressure amplifier (PA-1, Hans Rudolph) 117 
while respired gas fractions were sampled at the mouth and measured using an oxygen and 118 
carbon dioxide analyzer (ML 206, AD Instruments).  Blood pressure, HR, SPO2, V̇I, MSNA, and 119 
end-tidal gases were measured continuously throughout the experiment.  Cardiopulmonary 120 
measurements were recorded at 200 Hz while MSNA signals were recorded at 2 kHz using an 121 
analog-to-digital converter (Powerlab/16SP ML 880, AD Instruments) and commercially 122 
available software (LabChart V8, AD Instruments). 123 
The experimental protocol is shown in Figure 1.  Following acquisition of a stable, high 124 
quality MSNA signal, baseline measurements were obtained over 5-minutes to calculate the 125 
resting end-tidal partial pressures of O2 (PETO2) and carbon dioxide (PETCO2).  Dynamic end-126 
tidal forcing was then used to clamp PETO2 and PETCO2 at resting values independent of V̇I for 127 
the remainder of the LBNP protocol (Tymko et al., 2016).  LBNP was then applied at -15, -30, 128 
and -45 mm Hg with each stage held for three minutes.  Negative pressure within the box was 129 
continuously measured by a calibrated differential pressure signal amplifier (PA-1 Series 1100, 130 
Hans Rudolph).  To minimize the potential of dislodging the MSNA microelectrode, LBNP 131 
stages were not randomized.  BA MBV and diameter were acquired from the left arm during the 132 
last minute of baseline and at each LBNP stage.  Participants repeated a second LBNP protocol 133 
after 40-minutes of either IH (experimental) or air-breathing (time control).  Due to logistical 134 
limitations, the time control was conducted after the collection of the experimental group and 135 
utilized a separate sonographer.  Following baseline, dynamic end-tidal forcing was used to 136 
administer 40 consecutive 1-minute breathing cycles of IH, each comprising 40-seconds of 137 
hypercapnic hypoxia (targeting PETCO2 +6 mm Hg above baseline, PETO2 = 45 mm Hg) and 20-138 
seconds of normoxic recovery.  During the time control experiments, participants continued 139 
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breathing through the mouthpiece but did not undergo dynamic end-tidal forcing. The control of 140 
end-tidal and arterial blood gases using dynamic end-tidal forcing has been previously validated 141 
in our laboratory (Tymko et al., 2016).  This IH protocol mimicked the rate and magnitude of 142 
arterial oxyhaemoglobin desaturations observed in severe OSA patients during sleep (apnoea-143 
hypopnoea index ≥ 60 /hr).  Following each 40-minute intervention (i.e. IH or control), dynamic 144 
end-tidal forcing clamped PETO2 and PETCO2 at baseline levels and resting measurements were 145 
taken for 5-minutes. 146 
 147 
Analyses 148 
BA diameter was calculated from the ultrasound video images using automated edge detection 149 
software (Woodman et al., 2001).  BA MBV was obtained continuously from a Doppler audio 150 
signal translator (qDAT, Pennsylvania State University Hershey Medical Center, Hershey, PA).  151 
Forearm blood flow (Q̇BA; ml/min) was calculated as Q̇BA = BA MBV×π×BA radius2×60.  152 
Forearm vascular conductance (FVC; ml/min/mm Hg) was calculated as the quotient of Q̇BA and 153 
MAP.  We selected FVC over forearm vascular resistance as the independent variable because 154 
during LBNP, Q̇BA was reduced while MAP was maintained.  Under these conditions, the 155 
relationship between conductance and blood flow is linear (Lautt, 1989; Joyce et al., 2019).  156 
Mean, antegrade, and retrograde shear rate (SR) were calculated from BA MBV as four times the 157 
MBV divided by vessel diameter and from these the oscillatory shear index (OSI) was calculated 158 
[|retrograde SR|/(|antegrade SR| + |retrograde SR|)] (Tremblay et al., 2016).  Sympathetic bursts 159 
were determined by inspection of the integrated neurogram based on internationally accepted 160 
guidelines (White et al., 2015).  Bursts were classified as of muscle sympathetic origin if they 161 
occurred 1.2-1.4 seconds after a QRS complex, had a signal to noise ratio of >3:1, and exhibited 162 
a spiked morphology. Once bursts were identified, MSNA burst frequency (BF) was calculated 163 
and expressed as bursts/min.  Further, MSNA burst incidence (BI) was calculated and expressed 164 
as bursts/100 heart beats.  All respiratory, cardiovascular, and MSNA measures were extracted 165 
for each event (breath, beat and burst, respectively).  Data from the last minute of baseline and 166 
each LBNP stage were averaged at 1-minute intervals. 167 
To characterize the severity of IH delivered, the mean, mean minimum, and mean 168 
maximum SPO2, and time spent below 90%, 85%, and 80% SPO2 was determined.  SPO2 was 169 
calculated from PETO2 using the Severinghaus transformation (Severinghaus, 1979) to account 170 
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for circulatory time delays.  Since PETO2 over estimates arterial PO2 in normoxia and acute 171 
hypoxia (Tymko et al., 2016), and the Severinghaus transformation assumes a standard human 172 
blood oxyhaemoglobin dissociation curve, it is likely that the calculated SPO2 underestimates the 173 
true magnitude of desaturation during IH.  Additionally, breath-by-breath and beat-by-beat 174 
cardiorespiratory data were linearly interpolated at 1s intervals across IH and signal averaged for 175 
each subject [see Foster et al., (2009)].  To characterize each individual’s IH severity, the peak 176 
and nadir values from the average profiles for the total 40-minute exposure were extracted and 177 
compared by repeated measures ANOVA. 178 
 Breath-by-breath, beat-by-beat, and burst-by-burst data were averaged across the last 179 
minute of baseline and each LBNP stage and presented in absolute and relative changes from the 180 
pre-test baseline to account for any baseline group differences.  Subject characteristics were 181 
compared between groups by independent samples t-test.  Baseline data were compared 182 
statistically by linear mixed effect modelling, including fixed factors for group (IH vs Control) 183 
and time (Pre vs Post), and group-by-time interactions are reported.  Additionally, baseline 184 
changes within IH or control were assessed using a paired samples t-test and presented as the 185 
mean difference (Post minus Pre) with 95% confidence intervals.  Data from all stages of LBNP 186 
were compared statistically by linear mixed effect modelling and included fixed factors for group 187 
(IH vs Control), time (Pre vs Post) and LBNP stage (0, -15, -30, -45 mm Hg).  In all mixed 188 
models, subject identifiers were entered as a random effect within each group to control for 189 
correlation within subjects across fixed factors.  In addition, stage was entered as a random effect 190 
permitting slope to vary by subject across varying levels of LBNP.  When significant effects 191 
were identified, Tukey’s post-hoc was used to assess the relevant contrasts. 192 
Whole body sNVT was determined for each subject by determining the slope and 193 
intercept of the linear relationship between changes in MSNA BF and changes in DBP across all 194 
stages of LBNP (0, -15, -30, & -45 mm Hg) before and after IH or control (Halliwill et al., 195 
1996).  Similarly, forearm sNVT was determined for each subject by determining the slope and 196 
intercept of the linear relationship between changes in MSNA BF and changes in FVC before 197 
and after each treatment across all stages of LBNP.  Anticipating shifts in the integrated 198 
neurogram, which occur often and unpredictably during the course of graded LBNP, we elected, 199 
a priori, not to quantify MSNA burst amplitude or total MSNA.  The change in sNVT slopes and 200 
intercepts (post minus pre) were determined for IH and control and compared by a one-tailed 201 
 10 
independent samples t-test to determine the effect of treatment.  Additionally, the sNVT slopes 202 
and intercepts were compared within each treatment (IH or control) by paired samples t-tests. 203 
Data are expressed as means ± SD and mean differences with 95% confidence intervals.  All 204 
statistical analyses were conducted using R (R Core Team, 2018), lme4 (Bates et al., 2015), 205 
lmerTest (Kuznetsova et al., 2017), and emmeans (Lenth, 2019) statistical packages.  An alpha 206 




Twenty healthy males were enrolled.  One volunteer allocated to the control group was excluded 210 
because his nocturnal oxygen desaturation index was ≥ 5 events per hour. Three additional 211 
subjects, two from the control and one from the IH cohorts were excluded subsequently from 212 
group analyses because their neurograms or ultrasound images acquired during LBNP were of 213 
low quality.  The present analysis is therefore comprised of data assembled from 9 participants in 214 
the IH group and 7 in the control group.  Both cohorts were of similar age (IH: 23 ± 6, control: 215 
27 ± 8 years; P = 0.30), height (IH: 1.74 ± 0.09, control: 1.80 ± 0.08 m; P = 0.08), weight (IH: 79 216 
± 15, control: 80 ± 13 kg; P = 0.78), and BMI (IH: 26 ± 3, control: 25 ± 3 kg/m2; P = 0.40).  217 
Nocturnal oximetry and pulmonary function data are presented in Table 1.  218 
 219 
Intermittent Hypercapnia Hypoxia 220 
IH resulted in 40 bouts of hypercapnic hypoxaemia (mean minimum SPO2 of 83 ± 3 %) with full 221 
restoration of peripheral saturation between bouts (mean maximum SPO2 of 97 ± 0 %).  222 
Participants spent 37 ± 9 % of the exposure time with SPO2 < 90 %, 17 ± 12 % of time with SPO2 223 
< 85 %, and 3 ± 9 % of time with SPO2 < 80 %.  On average within each bout PETO2 was 224 
significantly reduced from 94 ± 9 to 48 ± 3 mm Hg during IH (P < 0.001), and PETCO2 was 225 
significantly increased from 41 ± 3 to 45 ± 3 mm Hg (P = 0.002) despite a concurrent increase in 226 
V̇I by 10 ± 6 l/min (P = 0.001). 227 
 228 
Baseline Cardiorespiratory, Sympathetic, and Haemodynamic Parameters following 229 
Intermittent Hypercapnic Hypoxia 230 
The influence of IH on baseline respiratory, cardiovascular, sympathetic, and haemodynamic 231 
parameters is presented in Table 2.  By study design, end-tidal gases were similar before and 232 
after IH and control.  V̇I was increased following IH but not control (group-by-time, P = 0.02).  233 
This effect tended to be driven by an increase in breathing frequency rather than tidal volume.  234 
Although MAP increased following IH (+5 mm Hg; 95% CI: 3 – 8; P = 0.002) but not control 235 
(+3 mm Hg; 95% CI: -3 – 9; P = 0.23), the effect lacked a significant group-by-time effect (P = 236 
0.31).  Similar observations were made with respect to SBP and DBP (Table 2).  Heart rate was 237 
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similar following IH and control, while MSNA BF and BI tended to be increased by IH but 238 
lacked significant group-by-time effects (P = 0.24).  IH tended to reduce Q̇BA and led to 239 
significant reductions in FVC and SR.  Antegrade SR tended to be reduced (IH: -22 /s; 95% CI: -240 
38 – -6; P = 0.01; Control: -3 /s; 95% CI: -24 – 17; P = 0.70; group-by-time, P = 0.08) while 241 
retrograde SR increased (IH: 2 /s; 95% CI: -0 – 4; P = 0.08; Control: -2 /s; 95% CI: -5 – 1; P = 242 
0.16; group-by-time, P = 0.01) by IH leading to a significant increase in the OSI (IH: 0.03; 95% 243 
CI: 0.01 – 0.05; P = 0.01; Control: -0.03; 95% CI: -0.08 – 0.03; P = 0.28; group-by-time, P = 244 
0.02).   245 
 246 
Influence of Intermittent Hypercapnic Hypoxia on Cardiorespiratory, Sympathetic, and 247 
Haemodynamic Responses to LBNP 248 
Figure 2 illustrates the haemodynamic and sympathetic response to LBNP from a representative 249 
subject before and after IH.  The pressure generated during each stage of LBNP was similar 250 
between pre- and post-tests (time effect; P = 0.66) and did not differ between IH and control 251 
(group effect; P = 0.57).  Mean LBNP for each stage was 16.1 ± 0.4, 30.3 ± 0.4, and 45.0 ± 0.4 252 
mm Hg.  253 
The influence of IH on respiratory, cardiovascular, sympathetic, and haemodynamic 254 
parameters during LBNP are presented in Table 3 and Figure 3.  PETO2 was similar across each 255 
stage of LBNP (stage effect, P = 0.46) but was modestly elevated (1.1 mm Hg; 95% CI: 0.1 – 256 
2.1; time effect, P = 0.02) in the post test across both groups.  PETCO2 was similar across each 257 
stage of LBNP (stage effect; P = 0.51) and across conditions (time effect; P = 0.45) for both 258 
groups.  V̇I increased across stages of LBNP in both IH and control (stage effect, P < 0.001).  259 
There was a significant group-by-time effect (P < 0.001; Figure 3A) suggesting that V̇I was 5.2 260 
l/min greater across all stages of LBNP following IH (95% CI: 4.2 – 6.2; P < 0.001) but not 261 
following control (-0.2 l/min; 95% CI: -1.4 – 1.0; P = 0.99).  This effect was driven by breathing 262 
frequency, since tidal volume was similar between groups (IH vs control; P = 0.21) and time (pre 263 
vs post; P = 0.96) across all levels of LBNP.  There was a significant group-by-time interaction 264 
(P = 0.01) for breathing frequency; whereby breathing frequency increased by 3 breaths/min 265 
following IH (95% CI: 1.0 – 5.0; P < 0.001) but not following control (1 breaths/min; 95% CI: -1 266 
– 3; P = 0.40). 267 
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 There were significant group-by-time interactions for MAP, SBP, and DBP (each P ≤ 268 
0.001).  Regardless of LBNP stage, MAP was 7 mm Hg higher following IH (95% CI: 5 – 9; P < 269 
0.001) but only 3 mm Hg higher following control (95% CI: 1 – 5; P = 0.01; Figure 3B).  SBP 270 
was reduced with increasing LBNP (P = 0.007).  Across all stages of LBNP, SBP was 9 mm Hg 271 
higher following IH (95% CI: 7 – 11; P < 0.001) but only 3 mm Hg higher following control 272 
(95% CI: 1 – 5; P = 0.12).  DBP tended to increase with increasing LBNP (stage effect, P = 0.06) 273 
and was 6 mm Hg higher following IH (95% CI: 4 - 8; P < 0.001) but only 3 mm Hg higher 274 
following control (95% CI: 1 – 5; P = 0.01).  HR increased with LBNP in both groups (stage 275 
effect, P < 0.001) but this response was larger in IH compared with control (P < 0.001; stage-by-276 
group interaction).  HR was lower in the control group compared with the IH group (group 277 
effect, P = 0.02) and was higher across all stages of LBNP following IH (2 /min; 95% CI: 1 – 3; 278 
P = 0.01) but not following control (0 /min; 95% CI: -1 – 1; P = 1.0). 279 
 With respect to MSNA BF the group-by-time-by-stage interaction (P = 0.11) and the 280 
group-by-time interaction were not significant (P = 0.18; Figure 3C).  MSNA BF increased with 281 
each stage of LBNP (stage effect, P < 0.001), was higher in the post test regardless of group (1.3 282 
/min; 95% CI: 0.3 – 2.3; time effect, P = 0.007) and was higher in the IH group (11 /min; 95% 283 
CI: 5 – 17; group effect, P = 0.002).  Similarly, MSNA BI increased with LBNP (stage effect, P 284 
< 0.001) but the group-by-time interaction was not significant (P = 0.15). 285 
 Q̇BA was reduced by LBNP (stage effect, P < 0.001) and there was a significant group-by-286 
time interaction (P = 0.02, Figure 3D).  Q̇BA was reduced to a greater extent following IH 287 
compared with control (IH: 16 ml/min, 95% CI: 11 – 21; P < 0.001; control: 7 ml/min, 95% CI: 288 
1 – 13; P = 0.06).  Similarly, SR was reduced by LBNP (stage effect, P < 0.001) and there was a 289 
significant group-by-time interaction (P = 0.01, Figure 3E).  Specifically, SR was reduced by 21 290 
/s following IH (95% CI: 15 – 27; P < 0.001) and to a lesser extent following control (10 /s, 95% 291 
CI: 2 – 18; P = 0.05; Figure 3E).  FVC decreased across LBNP (P < 0.001) and there was a 292 
significant group-by-time interaction (P = 0.003; Figure 3F).  IH reduced FVC by 0.23 293 
ml/min/mm Hg (95% CI: 0.17 – 0.29; P < 0.001) and to a lesser extent following control (0.10 294 
ml/min/mm Hg, 95% CI: 0.04 – 0.16; P = 0.02). 295 
 296 
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Sympathetic Neurovascular Transduction 297 
sNVT was assessed before and after IH or control using the slope and intercept of the 298 
relationship between the change in MSNA BF and the percent change in FVC (Figure 4) or 299 
absolute change in DBP (Figure 5) throughout LBNP.  The change in FVC transduction slope 300 
was similar between IH (-0.84 %/burst/min, 95% CI: -1.82 – 0.14) and control (-1.09 301 
%/burst/min, 95% CI: -3.01 – 0.82, Figure 4C).  Specifically, the difference in FVC transduction 302 
slope change was similar between groups (-0.25 %/burst/min, 95% CI: -1.88 – ∞; P = 0.61).  303 
Likewise, the change in FVC transduction intercept was similar following IH (-16.1 %, 95% CI: 304 
-31.9 – -0.3) and control (-6.4 %, 95% CI: -37.5 – 24.8, Figure 4D).  The difference in FVC 305 
transduction intercept change was similar between groups (9.8 %, 95% CI: -16.6 – ∞; P = 0.26).  306 
The DBP transduction slope was increased by IH (0.25 mm Hg/burst/min, 95% CI: 0.02 – 307 
0.48, P = 0.04) but not following control (0.00 mm Hg/burst/min, 95% CI: -0.18 – 0.18, P = 308 
0.99).  The DBP transduction slope change differed between groups (0.25 mmHg/burst/min, 95% 309 
CI: -∞ – 0.03; P = 0.03, Figure 5C).  The change in DBP transduction intercept was similar 310 
between IH (2.96, 95% CI: 0.02 – 5.89) and control (3.05, 95% CI: -2.66 – 8.77).  The DBP 311 
transduction intercept change was similar between groups (-0.1, 95% CI: -4.9 – ∞, P = 0.51, 312 
Figure 5D).  313 
 15 
DISCUSSION 314 
The purpose of this study was to determine the impact of acute exposure to IH on regional and 315 
systemic sNVT.  Our data demonstrate, for the first time, that systemic sNVT is augmented 316 
following IH.  Yet, changes in forearm sNVT were similar following IH and control.  We 317 
interpret these results to suggest regional differentiation in the neurovascular response to IH, 318 
which support an overall systemic increase in sNVT.  Additionally, IH led to a robust increase in 319 
V̇I, suggesting ventilatory long term facilitation (LTF), an increase in mean arterial pressure, and 320 
a reduction in vascular shear rate. 321 
 322 
Sympathetic Neurovascular Transduction 323 
We observed a significant increase in the DBP transduction slope after 40-minutes of IH (Figure 324 
5C), which did not occur in the control group, suggesting that systemic sNVT was increased by 325 
IH.  This effect differed in the forearm where similar changes in FVC transduction slope and 326 
intercept were observed following either IH or control (Figure 4).  Augmented sNVT has also 327 
been reported during continuous isocapnic hypoxia (Tan et al., 2013b).  Our results suggest that 328 
the systemic sNVT response to IH was more pronounced than the regional sNVT response 329 
measured in the forearm.  Differences in haemodynamics between upper and lower limbs during 330 
IH may explain why systemic sNVT was increased while changes are less evident in the forearm.  331 
In line with this hypothesis, leg sNVT measured at the femoral artery is greater than forearm 332 
sNVT (Fairfax et al., 2013a, 2013b), possibly owing to reduced responsiveness to α-adrenergic 333 
stimulation in the forearm (Pawelczyk & Levine, 2002).  Also, during IH the leg is exposed to a 334 
greater reduction in antegrade SR and increased OSI, compared with the forearm (Tremblay et 335 
al., 2016).  Since the leg receives a greater proportion of circulation compared with the forearm, 336 
changes in sNVT in the leg may contribute more to blood pressure control and whole body 337 
sNVT. 338 
The AT1R may have a role in augmenting sNVT after IH.  Blocking the AT1R with 339 
Losartan before intermittent hypoxia prevents the known increase in resting blood pressure 340 
(Foster et al., 2010), sympathetic vasomotor outflow (Jouett et al., 2017), oxidative stress 341 
(Pialoux et al., 2011), and endothelial dysfunction associated with intermittent hypoxia (Marcus 342 
et al., 2012).  Local infusion of angiotensin-II exacerbates the forearm vascular resistance 343 
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response to mild LBNP while having no effect on the response to local norepinephrine infusion 344 
(Seidelin et al., 1991), which supports the hypothesis that renin-angiotensin system mediated 345 
changes in sNVT may occur via presynaptic facilitation.  346 
An alternative explanation is that IH increases sNVT as a result of decreased NO 347 
production due to reductions in Q̇BA (reducing antegrade SR) and sympathetically-mediated 348 
increases in resistance vessel tone (increasing retrograde SR).  Additionally, as a result of an IH 349 
induced alteration in redox homeostasis, free-radical mediated scavenging of NO may further 350 
contribute to reductions in NO bioavailability.  Our results showed that IH reduced forearm SR 351 
and increased the OSI to a greater extent than control (Tables 2 & 3, Figure 3).  Nonetheless, 352 
there were modest but significant increases in DBP and reductions in FVC, Q̇BA, and SR (Table 353 
3) following control which may have contributed to the similar increase in forearm sNVT 354 
observed between IH and control.  Therefore, the effect on forearm sNVT may have less to do 355 
with IH and more to do with prolonged inactivity and consequent reductions in SR and NO 356 
production.  The greater systemic sNVT observed following IH, may be more related to the 357 
greater IH mediated reductions in vascular SR that we have previously observed within the 358 
vasculature of the lower limb (Tremblay et al., 2016).  In OSA, hypoxia-induced sympathetic 359 
activation is also believed to increase retrograde blood flow (Millar et al., 2011).  The observed 360 
changes in SR may be related to increased MSNA BF or sNVT, as retrograde SR and OSI are 361 
increased with sympathetic vasomotor outflow and reduced conductance during LBNP (Padilla 362 
et al., 2010) but alternatively could be due to local effects of IH on endothelial cell function.  363 
Although no studies have measured endothelial-dependent dilation after 40 minutes of IH, longer 364 
duration exposure to IH without hypercapnia reduces NO derivatives (Foster et al., 2009; 365 
Pialoux et al., 2011), promotes retrograde shear stress (Tremblay et al., 2016), reduces peak 366 
reactive hyperaemia and resting blood flow in the forearm, and increases baseline forearm 367 
vascular resistance (Gilmartin et al., 2010).  After 12 weeks of CPAP therapy in OSA patients 368 
whom are without comorbidities, NO expression in microcirculatory vessel walls increased 4-369 
fold alongside improved flow-mediated dilation, which supports that the absence of IH can 370 
improve endothelial function (Khayat et al., 2017).  However, in healthy young males, 6-hours 371 
of IH did not reduce flow-mediated dilation compared to controls (Tremblay et al., 2016).  372 
Animal studies have demonstrated that NO reduces the release of norepinephrine from 373 
sympathetic nerves and inactivates norepinephrine directly (Macarthur et al., 2011).  Therefore, 374 
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sNVT may have been increased in this study, through mechanisms reducing NO production 375 
(reduced Q̇BA) and bioavailability (alteration in redox homeostasis). 376 
 377 
Sympathetic Vasomotor Outflow and Blood Pressure 378 
IH tended to increase resting sympathetic vasomotor outflow (Table 2) and increased blood 379 
pressure throughout all stages of LBNP (Table 3, and Figure 3B).  Blood pressure and 380 
sympathetic responses after IH were independent of chemoreceptor stimulation, as end-tidal 381 
gases were clamped at baseline levels.  Generally, our results are similar to other studies which 382 
reported long-lasting increases in sympathetic vasomotor outflow after a short bout of 383 
intermittent or continuous hypoxia (Xie et al., 2000; Cutler, 2004; Leuenberger et al., 2005; 384 
Jouett et al., 2017). We observed an increase in MSNA BF in 89% of participants after IH, but 385 
only 43% of participants following control. The greater BP observed following IH across all 386 
stages of LBNP despite only a modest increase in MSNA BF following IH suggests an important 387 
regulatory role for systemic sNVT. 388 
 389 
Long Term Facilitation of Ventilation 390 
Ventilatory LTF describes plasticity in the neural control of respiration such that V̇I remains 391 
elevated following IH.  Our results show V̇I was increased following IH, independent from 392 
changes in arterial blood gases (Figure 3, Table 2 & 3).  In the control group, V̇I remained 393 
similar to baseline following 40-minutes of room air breathing (Table 2).  Previous studies in 394 
awake humans demonstrate ventilatory LTF following intermittent hypoxia only when combined 395 
with hypercapnia (PETCO2 ≈ 3-5 mm Hg above baseline) throughout both exposure and recovery 396 
(Harris et al., 2006; Mateika & Sandhu, 2011; Griffin et al., 2012), but not when PETCO2 is 397 
uncontrolled in recovery (Deacon et al., 2017).  The contrasting results with others may be a 398 
result of longer duration IH, longer period of hypoxia/hypercapnia, and shorter normoxic 399 
recovery periods.  The greater intensity of IH may have increased carotid body activation 400 
eliciting robust ventilatory LTF.  Future studies are needed to confirm our finding of ventilatory 401 
LTF following intermittent hypercapnic hypoxia. 402 
 403 
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Methodological Considerations 404 
We measured sNVT by increasing sympathetic vasomotor activity with LBNP and observing the 405 
forearm vascular (FVC) and systemic vasomotor (DBP) responses.  Specifically, we observed 406 
the strength of the relationship between MSNA BF and FVC or DBP before and immediately 407 
after acute IH.  Similar methods have been used previously to determine the effect of race and 408 
fitness on sNVT (Ray & Monahan, 2002; Notarius et al., 2012).  We improved upon these 409 
methods by using end-tidal forcing to clamp blood gases at baseline levels.  This is essential as 410 
the graded ventilatory response which accompanies LBNP would result in hypocapnia, reducing 411 
chemoreceptor activation and lowering sympathetic vasomotor outflow and peripheral vascular 412 
resistance through direct effects on the vessel (Burnum et al., 1954).  Handgrip exercise, which 413 
also increases ventilation, has similarly been used instead of LBNP to increase MSNA BF for the 414 
measurement of sympathetic transduction (Halliwill et al., 1996; Minson et al., 2000; Tamisier et 415 
al., 2015) but these studies also do not control for blood gas changes during sNVT measurement.  416 
Clamping blood gases at baseline levels prevents distortion of the relationship between MSNA 417 
BF and FVC, allowing for a more precise measurement of sNVT that is independent of 418 
secondary chemoreflex effects. 419 
Our sNVT technique is limited in that we are unable to measure transduction in a purely 420 
resting state, and it does not consider the dynamic changes in transduction that occur in response 421 
to each burst of MSNA.  By directly measuring sympathetic vasomotor activity and relating it to 422 
the observed strength of the vascular response, we are able to assess sNVT. However, in our 423 
current experimental paradigm, we are unable to determine the relative contributions of 424 
increased afferent activity from the peripheral chemoreceptors, reduced afferent activity from 425 
baroreceptors, or changes in the central gain of afferent-efferent transmission, to the increase in 426 
sympathetic outflow.  Previous studies have investigated burst-by-burst effects on subsequent 427 
changes in forearm and leg vascular conductance (Fairfax et al., 2013a, 2013b; Vranish et al., 428 
2018), diastolic blood pressure (Briant et al., 2016), and a complex autoregressive model of 429 
transduction independent of blood pressure during handgrip exercise (Tan et al., 2013a). 430 
However, our measure of sNVT informs the vascular responses over a wide range of sympathetic 431 
vasomotor activity.  Using LBNP to achieve graded increases in sympathetic vasomotor outflow 432 
permits the sensitivity of the vasculature beyond the resting state to be measured.  433 
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A strength of our experimental exposure to IH is the addition of hypercapnia to better 434 
simulate the blood gas changes in OSA.  However, we are unable to conclude whether 435 
intermittent hypoxia, intermittent hypercapnia, or the combination of the two is responsible for 436 
augmenting whole body sNVT.  Hypercapnia has been demonstrated to have a role in ventilatory 437 
LTF, respiratory muscle and phrenic nerve LTF, and carotid body sensory LTF (Peng et al., 438 
2003; Roy et al., 2018), all of which may have a role in controlling breathing stability and upper 439 
airway patency in OSA (Mahamed & Mitchell, 2007; Mateika & Syed, 2013). Therefore, it was 440 
important to include hypercapnia in our IH paradigm to better replicate changes in sNVT that 441 
may accompany OSA early in its progression. 442 
For logistical reasons, control group data were collected after the IH group was studied.  443 
This sequential approach may have contributed to significant between group differences at 444 
baseline in heart rate, which may reflect lower fitness, and in heart rate-coupled MSNA BF.  445 
Importantly, our analyses focused on intervention (i.e., IH or sham) effects. Whether fitness 446 
status influences the sNVT response to IH is unknown.  Additionally, the effect of IH on sNVT 447 
in females requires study.  448 
CONCLUSION 449 
In these experiments, systemic but not forearm sNVT was augmented after an acute 40-minute 450 
bout of IH.  Such selectivity may result from the known differential effects of IH on upper and 451 
lower limb vasculature (Tremblay et al., 2016).  Specifically, reductions in vessel wall shear rate, 452 
augmented oscillatory shear rate, and the consequent reductions in NO production may in part 453 
increase sNVT.  The larger volume of vasculature within the lower legs and greater reduction in 454 
shear rate observed in these limbs may explain the effect of IH on whole body sNVT.  The 455 
greater V̇I observed following IH is suggestive of ventilatory LTF. Our data adds to the body of 456 
evidence suggesting that IH has long-lasting effects on the arterial vasculature and leads to 457 
respiratory and neurocirculatory plasticity.  The variance between individuals in the sNVT 458 
response to IH might explain why some patients with OSA develop hypertension while others do 459 
not.  Our results provide a potential mechanism for increasing blood pressure in patients with 460 
OSA early in disease progression and may contribute to the increased risk of hypertension well 461 
documented in OSA patients. 462 
  463 
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TABLES AND FIGURES 
Table 1.  Participant nocturnal oximetry and pulmonary function 
data by intermittent hypercapnic hypoxia and control group. 
Variable IH Control P 
ODI (/hr) 2.4 ± 1.2 1.7 ± 1.1 0.35 
Mean Min. SpO2 (%) 92.2 ± 0.9 92.9 ± 1.1 0.30 
Forced vital capacity (l) 5.37 ± 0.78 5.97 ± 0.93 0.18 
Forced vital capacity (% predicted) 102 ± 12 111 ± 16 0.40 
FEV1 (l) 4.14 ± 0.48 4.63 ± 0.61 0.13 
FEV1 (% predicted) 94 ± 12 103 ± 11 0.28 
FEV1/Forced vital capacity (%) 78.0 ± 7.2 77.7 ± 3.7 0.81 
DLCO (% predicted) 97 ± 12 113 ± 8 0.10 
VA (l) 6.29 ± 0.96 7.13 ± 1.19 0.27 
DLCO/VA (% predicted) 103 ± 15 107 ± 11 0.46 
Values are means ± SD.  IH, N = 9; Control, N = 7.  Abbreviations: ODI, 
oxygen desaturation index; Mean Min. SpO2, mean minimum nocturnal 
peripheral oxyhaemoglobin saturation; FEV1, forced expiratory volume 
in 1 second; DLCO, diffusing capacity of the lung for carbon monoxide 
transfer; VA, alveolar volume; P, probability for difference between IH 
and Control based on an independent samples t-test. 
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Table 2. Influence of intermittent hypercapnic hypoxia on baseline respiratory, cardiovascular, 
sympathetic, and haemodynamic parameters. 
 







Respiratory        
  V̇I, l/min IH 9 11 ± 3 16 ± 3 5.1 {1.5 – 8.7}  0.01 0.02 
 Control 6 12 ± 2 12 ± 2 0.0 {-2.1 – 2.2}  0.99  
  VT, l IH 9 1.1 ± 0.3 1.1 ± 0.3 -0.0 {-0.3 – 0.3}  0.90 0.67 
 Control 6 1.1 ± 0.2 1.0 ± 0.2 -0.1 {-0.2 – 0.0}  0.10  
  fB, /min IH 9 10 ± 3 14 ± 3 3 {-0 – 7}  0.07 0.20 
 Control 6 10 ± 2 11 ± 2 1 {-1 – 3}  0.24  
  PETO2, mm Hg IH 9 92 ± 3 92 ± 3 0.4 {-3.4 – 4.1}  0.82 0.89 
 Control 7 94 ± 3 94 ± 3 0.1 {-1.8 – 2.0}  0.89  
  PETCO2, mm Hg IH 9 41 ± 3 41 ± 3 -0.4 {-1.1 – 0.2}  0.15 0.39 
 Control 7 40 ± 3 40 ± 3 0.2 {-1.8 – 2.3}  0.80  
Cardiovascular        
  SBP, mm Hg IH 9 122 ± 9 130 ± 9 7 {2 – 12}  0.01 0.27 
 Control 7 118 ± 11 121 ± 11 3 {-6 – 12}  0.43  
  DBP, mm Hg IH 9 68 ± 9 72 ± 9 5 {3 – 7} <0.01 0.36 
 Control 7 61 ± 3 63 ± 3 3 {-3 – 8}  0.26  
  HR, /min IH 9 64 ± 9 66 ± 9 2 {-2 – 5}  0.27 0.24 
 Control 7 55 ± 8 54 ± 8 -1 {-4 – 3}  0.66  
Sympathetic        
  MSNA BF, /min IH 9 17 ± 9 20 ± 9 3 {-0 – 6}  0.05 0.08 
 Control 7 12 ± 5 11 ± 5 -0 {-4 – 3}  0.76  
  MSNA BI, /100 HB IH 9 26 ± 12 31 ± 12 4 {-1 – 10}  0.11 0.10 
 Control 7 23 ± 16 21 ± 16 -2 {-8 – 5}  0.59  
Haemodynamic        
  FVC, ml/min/mm Hg IH 9 0.86 ± 0.39 0.62 ± 0.39 -0.24 {-0.40 – -0.08} <0.01 0.05 
Control 7 0.63 ± 0.21 0.59 ± 0.21 -0.04 {-0.22 – 0.14}  0.60  
  Q̇BA, ml/min IH 9 75 ± 36 57 ± 36 -17 {-33 – -2}  0.03 0.09 
Control 7 51 ± 19 49 ± 19 -2 {-15 – 11}  0.72  
  SR, /s IH 9 101 ± 48 77 ± 48 -24 {-39 – -8} <0.01 0.05 
Control 7 72 ± 32 70 ± 32 -1 {-23 – 21}  0.89  
Values are means ± SD or 95% confidence intervals {95% CI}. Definition of abbreviations: V̇I, minute ventilation; 
VT, tidal volume; fB, breathing frequency; PETO2, partial pressure of end-tidal O2; PETCO2, partial pressure of end-
tidal CO2; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; MSNA BF, muscle 
sympathetic nerve activity burst frequency; MSNA BI, muscle sympathetic nerve activity burst incidence; FVC, 
forearm vascular conductance; Q̇BA, brachial artery blood flow; SR, shear rate. Within Group (P), probability for a 
difference within IH or Control based on a paired-samples t-test.  Group by time (P), probability for a group-by-time 
interaction based on a linear mixed effect model including fixed factors for group and time. 
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Table 3. Influence of intermittent hypercapnic hypoxia on respiratory, cardiovascular, and 
haemodynamic parameters during LBNP. 
Variable   LBNP Level 
Group  Time 0 mm Hg -15 mmHg -30 mmHg -45 mm Hg 
Respiratory       
  V̇I, l/min Group: P = 0.14; Time: P < 0.001; Stage: P < 0.001; Group*Time: P < 0.001 
IH  PRE 11 ± 3 12 ± 3 13 ± 6 16 ± 6†  POST 16 ± 6* 18 ± 6* 20 ± 6* 22 ± 6*† 
Control  PRE 12 ± 3 13 ± 3 13 ± 3 14 ± 3†  POST 12 ± 3 12 ± 3 13 ± 5 14 ± 5† 
Cardiovascular       
  SBP, mm Hg Group: P = 0.56; Time: P < 0.001; Stage: P < 0.01; Group*Time: P < 0.001 
IH  PRE 122 ± 9 122 ± 9 115 ± 12 111 ± 12†  POST 130 ± 6* 128 ± 9* 126 ± 12* 123 ± 15*† 
Control  PRE 118 ± 11 121 ± 8 119 ± 8 115 ± 11†  POST 121 ± 8 123 ± 8 122 ± 11 119 ± 13† 
  DBP, mm Hg Group: P = 0.06; Time: P < 0.001; Stage: P = 0.06; Group*Time: P < 0.01 
IH  PRE 68 ± 9 69 ± 9 69 ± 12 68 ± 12  POST 72 ± 9* 73 ± 9* 75 ± 12* 75 ± 12* 
Control  PRE 61 ± 3 63 ± 3 63 ± 3 63 ± 3  POST 63 ± 5* 64 ± 5* 65 ± 5* 65 ± 8* 
  HR, /min Group: P < 0.01; Time: P < 0.05; Stage: P < 0.001; Group*Time: P < 0.05 
IH  PRE 64 ± 9 67 ± 12† 78 ± 12† 87 ± 12†  POST 66 ± 12 70 ± 15† 79 ± 12† 88 ± 15† 
Control  PRE 55 ± 8 56 ± 8 58 ± 8 63 ± 8†  POST 54 ± 5 56 ± 5 58 ± 5 63 ± 8† 
Sympathetic       
  MSNA BF, /min Group: P < 0.01; Time: P < 0.01; Stage: P < 0.001; Group*Time: P = 0.18 
IH  PRE 17 ± 9 23 ± 9† 29 ± 6† 36 ± 9†  POST 20 ± 6 27 ± 9† 32 ± 6† 34 ± 9† 
Control  PRE 12 ± 5 14 ± 5† 17 ± 5† 21 ± 5†  POST 11 ± 5 15 ± 5† 19 ± 8† 22 ± 8† 
  MSNA BI, /100 HB Group: P = 0.13; Time: P = 0.06; Stage: P < 0.001; Group*Time: P = 0.15 
IH  PRE 26 ± 12 35 ± 12† 37 ± 9† 42 ± 9†  POST 31 ± 12 40 ± 12† 41 ± 9† 39 ± 9† 
Control  PRE 23 ± 16 26 ± 13† 31 ± 11† 35 ± 13†  POST 21 ± 13 27 ± 11† 33 ± 13† 35 ± 11† 
Haemodynamic       
  FVC, ml/min/mm Hg Group: P = 0.47; Time: P < 0.001; Stage: P < 0.001; Group*Time: P < 0.01 
IH  PRE 0.86 ± 0.39 0.62 ± 0.36† 0.73 ± 0.39† 0.71 ± 0.33  POST 0.62 ± 0.36* 0.48 ± 0.30*† 0.46 ± 0.24*† 0.44 ± 0.18* 
Control  PRE 0.63 ± 0.21 0.50 ± 0.11† 0.58 ± 0.26† 0.60 ± 0.24  POST 0.59 ± 0.26* 0.42 ± 0.19*† 0.43 ± 0.13*† 0.46 ± 0.21* 
  Q̇BA, ml/min Group: P = 0.33; Time: P < 0.001; Stage: P < 0.001; Group*Time: P < 0.05 
IH  PRE 75 ± 36 55 ± 36† 62 ± 36† 59 ± 33†  POST 57 ± 36* 45 ± 27*† 43 ± 27*† 41 ± 21*† 
Control  PRE 51 ± 19 41 ± 8† 47 ± 21† 48 ± 21†  POST 49 ± 24 35 ± 16† 36 ± 11† 38 ± 19† 
  SR, /s Group: P = 0.42; Time: P < 0.001; Stage: P < 0.001; Group*Time: P < 0.05 
IH  PRE 101 ± 48 77 ± 51† 88 ± 51† 82 ± 30  POST 77 ± 51* 62 ± 42*† 62 ± 39*† 58 ± 27* 
Control  PRE 72 ± 32 59 ± 19† 71 ± 32† 70 ± 29  POST 70 ± 29* 53 ± 16*† 54 ± 16*† 55 ± 19* 
Values are means ± SD. Bold type IH or Control indicates a main effect of group, with the bold group possessing 
a higher value. *, P < 0.05 compared to PRE within each group. †, P < 0.05 compared to '0' LBNP. Definition 
of abbreviations: V̇I, minute ventilation; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart 
rate; MSNA BF, muscle sympathetic nerve activity burst frequency; MSNA BI, muscle sympathetic nerve activity 
burst incidence; FVC, forearm vascular conductance; Q̇BA, brachial artery blood flow; SR, shear rate.  Data 
were compared with a mixed effects linear model including fixed factors for group, time, and stage of LBNP and 
random effects for subject ID.
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Figure Legends 
Figure 1. Experimental protocol schematic.  
Abbreviations: BA MBV, brachial artery mean blood velocity; LBNP, lower body negative 
pressure. 
Figure 2. Haemodynamic and sympathetic vasomotor activity from a single 
representative subject during LBNP before (Pre; filled circles) and following (Post; open 
circles) intermittent hypercapnic hypoxia.  
Presented data includes lower body negative pressure (LBNP), beat-by-beat mean arterial 
pressure (MAP), brachial artery blood flow (Q̇BA), and the integrated sympathetic neurogram. 
Shown data is the final minute of each three-minute stage. Abbreviations: a.u., arbitrary units. 
Figure 3. Change (Post – Pre) in cardiorespiratory, haemodynamic, and sympathetic 
vasomotor outflow variables averaged across all stages of LBNP for control and IH.  
Data are means ± SEM illustrating the main effect of condition (IH vs Control) across 
baseline and all stages of LBNP.  Statistical testing by mixed effect linear model with fixed 
factors for group, time, and stage of LBNP, and random factors for subject ID.  *, P < 0.05 
represents a significant treatment effect between IH and control.  Abbreviations: V̇I, minute 
ventilation; MAP, mean arterial pressure, MSNA BF, muscle sympathetic nerve activity burst 
frequency; Q̇BA, brachial artery blood flow; SR, shear rate; FVC, forearm vascular 
conductance. 
 
Figure 4.  Sympathetic neurovascular transduction measured by forearm vascular 
conductance (FVC) before and after control (A) or IH (B), and the change in FVC 
transduction slope (C) and intercept (D).  
The mean coefficient of determination (r2) for the relationship between the change in FVC 
and MSNA BF were 0.41 ± 0.10 and 0.53 ± 0.10 for the IH group before (pre) and following 
(post) IH, respectively.  In the control group they were 0.20 ± 0.06 for pre and 0.37 ± 0.12 
for post.  In top panels (A and B), data are derived from measurements made during the four 
stages of LBNP (0, -15, -30, -45), pre is represented in white circles and dashed lines while 
post is shown in black circles and solid lines. In all panels, data are means ± SEM. In panels, 
C and D, data points are individual differences in FVC transduction slope and intercept.  
Statistical comparisons made by independent samples t-test. Control, N = 7; IH, N = 9. 
 
Figure 5.  Sympathetic neurovascular transduction measured by diastolic blood pressure 
(DBP) before and after control (A) or IH (B), and the change in DBP transduction slope 
(C) and intercept (D).  
The mean coefficient of determination (r2) for the relationship between the change in DBP 
and MSNA BF were 0.48 ± 0.10 and 0.51 ± 0.11 for the IH group before (pre) and following 
(post) IH, respectively.  In the control group they were 0.32 ± 0.10 for pre and 0.59 ± 0.10 
for post.  In top panels (A and B), data are derived from measurements made during the four 
stages of LBNP (0, -15, -30, -45), pre is represented in white circles and dashed lines while 
post is shown in black circles and solid lines.  In all panels, data are means ± SEM.  In 
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panels C and D, data points are individual differences in DBP transduction slope and 













Figure 1. Experimental protocol schematic.  
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Figure 2. Haemodynamic and sympathetic vasomotor activity from a single representative 
subject during LBNP before (Pre; filled circles) and following (Post; open circles) 
intermittent hypercapnic hypoxia.  
Presented data includes lower body negative pressure (LBNP), beat-by-beat mean arterial 
pressure (MAP), brachial artery blood flow (Q̇BA), and the integrated sympathetic neurogram. 






















































Figure 3. Change (Post – Pre) in cardiorespiratory, haemodynamic, and sympathetic 
vasomotor outflow variables averaged across all stages of LBNP for control and IH.  
Data are means ± SEM illustrating the main effect of condition (IH vs Control) across 
baseline and all stages of LBNP.  *, P < 0.05 represents a significant treatment effect 
between IH and control.  Abbreviations: V̇I, minute ventilation; MAP, mean arterial 
pressure, MSNA BF, muscle sympathetic nerve activity burst frequency; Q̇BA, brachial artery 














































































































































































Figure 4.  Sympathetic neurovascular transduction measured by forearm vascular 
conductance (FVC) before and after control (A) or IH (B), and the change in FVC 
transduction slope (C) and intercept (D).  
The mean coefficient of determination (r2) for the relationship between the change in FVC 
and MSNA BF were 0.41 ± 0.10 and 0.53 ± 0.10 for the IH group before (pre) and following 
(post) IH, respectively.  In the control group they were 0.20 ± 0.06 for pre and 0.37 ± 0.12 
for post.  In top panels (A and B), data are derived from measurements made during the four 
stages of LBNP (0, -15, -30, -45), pre is represented in white circles and dashed lines while 
post is shown in black circles and solid lines. In all panels, data are means ± SEM. In panels, 
C and D, data points are individual differences in FVC transduction slope and intercept. 
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Figure 5.  Sympathetic neurovascular transduction measured by diastolic blood pressure 
(DBP) before and after control (A) or IH (B), and the change in DBP transduction slope 
(C) and intercept (D).  
The mean coefficient of determination (r2) for the relationship between the change in DBP 
and MSNA BF were 0.48 ± 0.10 and 0.51 ± 0.11 for the IH group before (pre) and following 
(post) IH, respectively.  In the control group they were 0.32 ± 0.10 for pre and 0.59 ± 0.10 
for post.  In top panels (A and B), data are derived from measurements made during the four 
stages of LBNP (0, -15, -30, -45), pre is represented in white circles and dashed lines while 
post is shown in black circles and solid lines.  In all panels, data are means ± SEM.  In 
panels C and D, data points are individual differences in DBP transduction slope and 
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P = 0.51P = 0.03
